Archive · 8 Nov 2025
Pfizer Acquires Metsera in $10 Billion Deal After Bidding War
Pfizer, a big company that makes medicines, has decided to buy a smaller company called Metsera.
Metsera is working on drugs to help people lose weight.
There was a competition to buy Metsera, with another company named Novo Nordisk also wanting it.
Pfizer offered a lot of money, up to $10 billion, for Metsera.
Metsera's leaders looked at the offers and decided Pfizer's deal was the best for the people who own parts of Metsera.
So, Pfizer is set to buy Metsera, but the deal isn't totally finished yet.
Pfizer has agreed to acquire weight-loss drug startup Metsera Inc. for up to $10 billion.
The deal includes an initial cash payment and potential future payments based on performance milestones.
Pfizer won out over rival Novo Nordisk in a competitive bidding process for Metsera.
Metsera's board has recommended Pfizer's offer as the best transaction for its shareholders.
The acquisition is not yet officially closed but Pfizer is positioned to win the bidding.
- Who
- Pfizer Inc. and Metsera Inc. board of directors
- What
- Pfizer has agreed to acquire Metsera Inc. in a deal valued at up to $10 billion.
- When
- Late Friday
- Where
- Metsera Inc. announced the agreement.
- Why
- Metsera's board determined Pfizer's bid was the best transaction for its shareholders following a bidding competition with Novo Nordisk.
Novo Nordisk
Pfizer
Acquisition of Metsera
Novo Nordisk
Novo Nordisk engaged in a bidding war with Pfizer for Metsera.
Pfizer
Pfizer ultimately agreed to acquire Metsera for up to $10 billion, including potential milestone payments.
- Acquiring Company
- Pfizer Inc.
- Target Company
- Metsera Inc.
- Deal Value
- Up to $10 billion
- Deal Structure
- Up to $86.25 per share, including initial cash and potential milestone payments.
- Competitor
- Novo Nordisk A/S
